The Portuguese legislation released, 1 July 2018, has further liberalized the cultivation, manufacturing, import, export, distribution, and production of Medical Cannabis. In fact, Portugal now has ideal conditions for this type of business in terms of legislation, liberalized genetics, no quota constraints on quantities, optimum climate, export, and no limits on the compound of THC on the product portfolio.
BudFarma has already establish institutional partnerships for R&D with the most prestigious State University of Portugal, for its science and engineering programs. BudFarma with the University in a consortium, are currently applying for state funds for industrial R&D specifically for Medical Cannabis. Other State Funded projects with International Universities are currently in progress.
The company has acquired expert competencies in the cultivation of different Medical Cannabis strains, Biotechnology and Phytotechnology expertise to assure the success of the products. We are currently developing partnerships to assure in becoming a key player in this global industry.
BudFarma has submitted license applications, 31 July 2020, to Cultivate, Import and Export. The land for all of the operations such as cultivation has an area of 8.3 hectares starting with 6 greenhouses and with 6 different varieties with an annual production of 6,6 tons of dried medical cannabis flower. However, the production potential is 100Tons/year.
An LOI has been sign to supply the Swiss market with a minimum of 200Kg per month of GMP dried cannabis flowers.
At the moment we are looking to partner with equity investors in this project. Should you require more information, please contact us at: [email protected]